Medscape1 天
Recommendations and Rationale for the Treatment of Pelvic Inflammatory Disease
Ampicillin/sulbactam 3 g iv. q 6 h for 48 h iv. vial: (2 g:1 g) for 48 h US$80 ‡ Ceftriaxone 1 g iv. q 12 h for 48 h iv. vial: (250 mg) US$3; iv. vial: (2 g) for 48 h US$18.28 ‡ Cefixime 400 ...
Medscape1 天
Recommendations and Rationale for the Treatment of Pelvic Inflammatory Disease
Ampicillin/sulbactam 3 g iv. q 6 h for 48 h iv. vial: (2 g:1 g) for 48 h US$80 ‡ Ceftriaxone 1 g iv. q 12 h for 48 h iv. vial: (250 mg) US$3; iv. vial: (2 g) for 48 h US$18.28 ‡ Cefixime 400 ...
Morningstar5 天
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO ...
Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug XACDURO® (sulbactam-durlobactam ...
Yahoo Finance5 天
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO ...
announced today a strategic collaboration for the novel antibacterial drug XACDURO ® (sulbactam-durlobactam) in mainland China. Pfizer’s affiliated companies will be exclusively authorized to ...
BioSpace5 天
Zai Lab and Pfizer Announce Strategic Collaboration on the Novel Antibacterial Drug XACDURO ...
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab (“Zai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (“Pfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial drug ...